Supreme Greens settlement
This article was originally published in The Tan Sheet
Executive Summary
Supreme Greens developer Alejandro Guerrero and his company Health Solutions will pay $65,000 or transfer to FTC the title to Guerrero's 2004 Cadillac Escalade for allegedly claiming that Supreme Greens could prevent, treat or cure cancer, heart disease, arthritis and diabetes, the commission announces Oct. 6. The herbal supplement also was promoted for substantial weight loss. Healthy Solutions and two other individuals will also pay a combined total of $15,000. The settlement has two avalanche clauses for a $4.17 mil. total. FTC filed the complaint in June 2004, litigation is still pending against ITV Direct, Direct Marketing Concepts and other others (1"The Tan Sheet" July 5, 2004, In Brief) ...
You may also be interested in...
FTC & Supreme Greens
Direct Marketing Concepts, ITV Direct and Donald Barrett are barred from claiming that dietary supplement Supreme Greens with MSM treats, cures or prevents cancer, diabetes, arthritis and heart disease under a preliminary injunction obtained by the Federal Trade Commission announced July 2. The defendants also must prominently display disclaimers that infomercials aired to promote the product are paid advertisements, and may not sell or distribute products or services by means of a continuity program without informed consent from the consumer, according to the ruling. FTC filed charges in June 2004 alleging the defendants had deceptively marketed Supreme Greens through an infomercial, failed to disclose the program was a paid promotion and charged credit cards for automatic product shipments without consent...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.